USD 1.72
(-1.15%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 70.19 Million USD | 89.43% |
2022 | 37.05 Million USD | 66.62% |
2021 | 22.23 Million USD | 21.05% |
2020 | 18.37 Million USD | 55.89% |
2019 | 11.78 Million USD | -58.41% |
2018 | 28.33 Million USD | -30.04% |
2017 | 40.5 Million USD | 35.63% |
2016 | 29.86 Million USD | 70.99% |
2015 | 17.46 Million USD | 52.16% |
2014 | 11.47 Million USD | 51.96% |
2013 | 7.55 Million USD | 53.59% |
2012 | 4.91 Million USD | 41.23% |
2011 | 3.48 Million USD | 3.26% |
2010 | 3.37 Million USD | -7.61% |
2009 | 3.65 Million USD | -13.28% |
2008 | 4.2 Million USD | 9.33% |
2007 | 3.85 Million USD | 5.29% |
2006 | 3.65 Million USD | 0.22% |
2005 | 3.64 Million USD | 593.79% |
2004 | 525.97 Thousand USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 19.83 Million USD | 2.25% |
2024 Q2 | 22.15 Million USD | 11.72% |
2023 Q1 | 14.7 Million USD | 14.03% |
2023 Q4 | 19.39 Million USD | 0.25% |
2023 FY | 70.19 Million USD | 89.43% |
2023 Q2 | 16.74 Million USD | 13.91% |
2023 Q3 | 19.35 Million USD | 15.56% |
2022 Q2 | 6.9 Million USD | 13.05% |
2022 FY | 37.05 Million USD | 66.62% |
2022 Q3 | 11.15 Million USD | 61.58% |
2022 Q4 | 12.89 Million USD | 15.57% |
2022 Q1 | 6.1 Million USD | 1.55% |
2021 Q3 | 5.49 Million USD | -3.14% |
2021 Q4 | 6.01 Million USD | 9.43% |
2021 FY | 22.23 Million USD | 21.05% |
2021 Q1 | 5.05 Million USD | 17.9% |
2021 Q2 | 5.67 Million USD | 12.16% |
2020 Q2 | 4.94 Million USD | 0.0% |
2020 FY | 18.37 Million USD | 55.89% |
2020 Q1 | 4.94 Million USD | 983.33% |
2020 Q4 | 4.29 Million USD | 0.0% |
2020 Q3 | 4.29 Million USD | -13.16% |
2019 Q4 | 456 Thousand USD | 0.0% |
2019 FY | 11.78 Million USD | -58.41% |
2019 Q1 | 5.43 Million USD | -2.89% |
2019 Q2 | 5.43 Million USD | 0.0% |
2019 Q3 | 456 Thousand USD | -91.61% |
2018 Q4 | 5.59 Million USD | 0.0% |
2018 FY | 28.33 Million USD | -30.04% |
2018 Q1 | 8.6 Million USD | 5.86% |
2018 Q2 | 8.6 Million USD | 0.0% |
2018 Q3 | 5.59 Million USD | -34.9% |
2017 Q3 | 8.12 Million USD | -33.03% |
2017 Q2 | 12.13 Million USD | 0.0% |
2017 Q4 | 8.12 Million USD | 0.0% |
2017 Q1 | 12.13 Million USD | 42.5% |
2017 FY | 40.5 Million USD | 35.63% |
2016 Q4 | 8.51 Million USD | 0.0% |
2016 Q1 | 6.47 Million USD | 32.36% |
2016 Q3 | 8.51 Million USD | 31.52% |
2016 Q2 | 6.47 Million USD | 0.0% |
2016 FY | 29.86 Million USD | 70.99% |
2015 Q1 | 3.93 Million USD | 14.46% |
2015 Q3 | 4.89 Million USD | 24.43% |
2015 Q4 | 4.89 Million USD | 0.0% |
2015 FY | 17.46 Million USD | 52.16% |
2015 Q2 | 3.93 Million USD | 0.0% |
2014 Q2 | 2.4 Million USD | 0.0% |
2014 FY | 11.47 Million USD | 51.96% |
2014 Q4 | 3.43 Million USD | 0.0% |
2014 Q3 | 3.43 Million USD | 42.94% |
2014 Q1 | 2.4 Million USD | 34.57% |
2013 Q2 | 1.99 Million USD | 0.0% |
2013 FY | 7.55 Million USD | 53.59% |
2013 Q1 | 1.99 Million USD | 22.3% |
2013 Q3 | 1.78 Million USD | -10.39% |
2013 Q4 | 1.78 Million USD | 0.0% |
2012 Q2 | 1.22 Million USD | 0.0% |
2012 Q1 | 1.22 Million USD | 41.23% |
2012 Q3 | 1.66 Million USD | 35.27% |
2012 Q4 | 1.62 Million USD | -2.07% |
2012 FY | 4.91 Million USD | 41.23% |
2011 Q1 | 870.64 Thousand USD | 3.26% |
2011 Q4 | 870.64 Thousand USD | 0.0% |
2011 FY | 3.48 Million USD | 3.26% |
2011 Q2 | 870.64 Thousand USD | 0.0% |
2011 Q3 | 870.64 Thousand USD | 0.0% |
2010 Q4 | 843.19 Thousand USD | 0.0% |
2010 Q2 | 843.19 Thousand USD | 0.0% |
2010 Q3 | 843.19 Thousand USD | 0.0% |
2010 Q1 | 843.19 Thousand USD | -7.61% |
2010 FY | 3.37 Million USD | -7.61% |
2009 Q1 | 912.65 Thousand USD | -13.28% |
2009 Q3 | 912.65 Thousand USD | 0.0% |
2009 FY | 3.65 Million USD | -13.28% |
2009 Q4 | 912.65 Thousand USD | 0.0% |
2009 Q2 | 912.65 Thousand USD | 0.0% |
2008 Q2 | 1.05 Million USD | 0.0% |
2008 Q4 | 1.05 Million USD | 0.0% |
2008 Q1 | 1.05 Million USD | 9.33% |
2008 Q3 | 1.05 Million USD | 0.0% |
2008 FY | 4.2 Million USD | 9.33% |
2007 Q3 | 962.64 Thousand USD | 0.0% |
2007 FY | 3.85 Million USD | 5.29% |
2007 Q4 | 962.64 Thousand USD | 0.0% |
2007 Q1 | 962.64 Thousand USD | 5.29% |
2007 Q2 | 962.64 Thousand USD | 0.0% |
2006 Q3 | 914.29 Thousand USD | 0.0% |
2006 Q2 | 914.29 Thousand USD | 0.0% |
2006 Q1 | 914.29 Thousand USD | 0.22% |
2006 FY | 3.65 Million USD | 0.22% |
2006 Q4 | 914.29 Thousand USD | 0.0% |
2005 FY | 3.64 Million USD | 593.79% |
2005 Q2 | 912.28 Thousand USD | 0.0% |
2005 Q3 | 912.28 Thousand USD | 0.0% |
2005 Q1 | 912.28 Thousand USD | 593.79% |
2005 Q4 | 912.28 Thousand USD | 0.0% |
2004 Q4 | 131.49 Thousand USD | 0.0% |
2004 Q2 | 131.49 Thousand USD | 0.0% |
2004 Q3 | 131.49 Thousand USD | 0.0% |
2004 Q1 | 131.49 Thousand USD | 0.0% |
2004 FY | 525.97 Thousand USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Aclaris Therapeutics, Inc. | 31.24 Million USD | -124.625% |
Applied DNA Sciences, Inc. | 13.36 Million USD | -425.104% |
Aspira Women's Health Inc. | 9.15 Million USD | -666.801% |
Biodesix, Inc. | 49.08 Million USD | -42.997% |
BioNexus Gene Lab Corp. | 9.77 Million USD | -618.395% |
bioAffinity Technologies, Inc. | 2.53 Million USD | -2671.689% |
bioAffinity Technologies, Inc. | 2.53 Million USD | -2671.689% |
Bionano Genomics, Inc. | 36.11 Million USD | -94.354% |
CareDx, Inc | 280.32 Million USD | 74.96% |
Check-Cap Ltd. | - USD | -Infinity% |
Castle Biosciences, Inc. | 219.78 Million USD | 68.063% |
DarioHealth Corp. | 20.35 Million USD | -244.895% |
Exact Sciences Corporation | 2.49 Billion USD | 97.192% |
Fulgent Genetics, Inc. | 289.21 Million USD | 75.73% |
Guardant Health, Inc. | 563.94 Million USD | 87.553% |
ICON Public Limited Company | 8.12 Billion USD | 99.136% |
IDEXX Laboratories, Inc. | 3.66 Billion USD | 98.083% |
Illumina, Inc. | 4.5 Billion USD | 98.442% |
Intelligent Bio Solutions Inc. | 3.11 Million USD | -2155.718% |
iSpecimen Inc. | 9.92 Million USD | -607.007% |
Standard BioTools Inc. | 106.34 Million USD | 33.992% |
23andMe Holding Co. | 219.63 Million USD | 68.042% |
Medpace Holdings, Inc. | 1.88 Billion USD | 96.278% |
Myriad Genetics, Inc. | 678.4 Million USD | 89.653% |
Mainz Biomed B.V. | 895.47 Thousand USD | -7738.598% |
ENDRA Life Sciences Inc. | - USD | -Infinity% |
NeoGenomics, Inc. | 591.64 Million USD | 88.136% |
Neogen Corporation | 924.22 Million USD | 92.405% |
Inotiv, Inc. | 572.42 Million USD | 87.738% |
Natera, Inc. | 1.08 Billion USD | 93.516% |
OPKO Health, Inc. | 863.49 Million USD | 91.871% |
Psychemedics Corporation | 22.09 Million USD | -217.644% |
Prenetics Global Limited | 21.74 Million USD | -222.835% |
Prenetics Global Limited | 21.74 Million USD | -222.835% |
Precipio, Inc. | 15.19 Million USD | -361.887% |
Personalis, Inc. | 73.48 Million USD | 4.475% |
RadNet, Inc. | 1.61 Billion USD | 95.658% |
Sera Prognostics, Inc. | 306 Thousand USD | -22838.889% |
Sotera Health Company | 1.04 Billion USD | 93.31% |
Neuronetics, Inc. | 71.34 Million USD | 1.619% |
Star Equity Holdings, Inc. | 45.78 Million USD | -53.31% |
Star Equity Holdings, Inc. | 45.78 Million USD | -53.31% |
Trinity Biotech plc | 56.83 Million USD | -23.51% |
Twist Bioscience Corporation | 312.97 Million USD | 77.572% |
Exagen Inc. | 52.54 Million USD | -33.579% |